EBV virus positive

We can judge the outbreak of each disease through blood tests and checking the positive and negative status of viral antibodies, but we need to understand the relationship between these diseases. For example, when the EBV virus test is positive, most of you don’t know what disease it will cause, what clinical symptoms it has, etc. Therefore, we recommend that you learn more about related articles, which will be of great help in your prevention and treatment of EBV virus positivity.

Introduction to Epstein-Barr virus antibody (EBV-Ab): Epstein-Barr virus is a new human virus discovered in 1964 and is the pathogen of infectious mononucleosis. Young children and adolescents are susceptible to infection.

Epstein-Barr virus (EBV) is closely related to nasopharyngeal carcinoma. Nasopharyngeal carcinoma is one of the most common cancers in southern my country. Normal value of EBV-Ab: Heterophile agglutination test: <1:7 (or negative) Anti-EBV.IgG: negative Anti-EBV.IgM: negative Clinical significance of EBV-Ab:

(1) Increased: more common in infectious mononucleosis: anti-EBV. IgM shows a positive reaction, and the xenophilic antibodies appearing in the patient's blood reach a peak in 3-4 weeks, and a diagnosis can be confirmed when the titer exceeds 1:224.

(2) Anti-EBV.IgG positive: Consider a history of infection, but anti-EBV.IgM positive can prove recent infection.

(3) Increased levels are also common in children with malignant lymphoma and some nasopharyngeal carcinoma patients.

(4) The blood of patients with serum sickness and some normal people may contain a small amount of heterophilic antibodies. Nasopharyngeal carcinoma is closely related to Epstein-Barr virus. The method of early diagnosis is to use some means of viral serology to take a drop of blood from the ear or hand of the subject for testing to see if Epstein-Barr virus immunoglobulin A antibodies can be detected, including antibodies against the capsid antigen and early antigen of Epstein-Barr virus. If these two antibodies are positive, the proportion of patients suffering from nasopharyngeal cancer is 2% and 30% to 40% respectively.

Generally speaking, combined chemotherapy and radiotherapy is the mainstream treatment for later-stage NPC, while patients with early-stage NPC usually only receive radiotherapy. The study found that among 208 patients with early stage II nasopharyngeal carcinoma, 98 were arranged to undergo two to three sets of chemotherapy before receiving radiotherapy, while the rest only received radiotherapy. The five-year survival rate for patients who received only radiotherapy was 67%, while the survival rate for patients who received guided chemotherapy and radiotherapy increased to 80%.

The lower survival rate for patients who receive only radiotherapy is because 22% of patients have metastatic tumors. These cancer cells have actually spread during treatment but cannot be detected and treated. In the combined therapy, the patient was first arranged to undergo chemotherapy, which reduced the spread rate to 12%. Guided chemotherapy helps to eliminate tumors that have already spread as early as possible, causing tumors in the nasopharynx and neck to shrink before radiotherapy. In addition, combined therapy can help patients control their tumors while waiting for radiation therapy.

The above is an article introduction about "The close relationship between nasopharyngeal carcinoma and Epstein-Barr virus". For many cancer patients, the most worrying thing after surgery to remove the tumor is metastasis and recurrence. Once metastasis and recurrence occur, it will increase the difficulty of treatment and the patient is likely to lose his life. Experts say that using CLS autologous immune cell therapy immediately after surgery can quickly clear scattered cancer cells and tiny lesions, effectively prevent tumor recurrence and metastasis, and gradually improve immunity.